Onego Bio Ltd: Precision Fermentation for European Food Security and Strategic Autonomy
32 pages · PDF · 22 August 2025 · Licensed single-user copy, watermarked to the buyer
€499 excl. VAT — EU VAT calculated at checkout (VAT ID accepted for reverse charge); invoice issued after payment
One click to Stripe — guest checkout, no account. Your download appears on the confirmation page and arrives by e-mail right after payment (link valid 72 hours, up to 5 downloads).
About this report
Onego Bio Ltd is redefining how Europe can produce a staple protein—egg white—without a single chicken. This Finnish biotech spin-off has emerged from a national research lab with a mission that resonates far beyond the food industry .
By using precision fermentation to create real ovalbumin (the key egg white protein) in yeast-like bioreactors, Onego Bio offers a glimpse into a more resilient and sustainable food supply. Its innovative Bioalbumen powder delivers the full functionality of egg whites without the environmental or biosecurity risks of poultry farming.
Key questions this report answers
- How does Onego Bio use precision fermentation to produce real ovalbumin (Bioalbumen) without poultry?
- How does animal-free egg-white protein support European food security and reduce biosecurity risks?
- How mature is the technology, from research lab to production?
- What are Onego Bio's capability gaps, dependencies and strategic indicators?
Inside this report
- Executive Summary
- Corporate Identity & Legal Structure
- Strategic Business Profile
- Technology Portfolio Mapping
- Technology Readiness Assessment
- European Strategic Program Participation
- Academic & Research Origins
- Dual-Use Applications & European Market Strategy
- Strategic Partnerships & European Industrial Alliances
- European Market Focus & Operational Domains
- Intellectual Property & European Innovation Assets
- Leadership & European Technical Expertise
- Capability and Gap Analysis
- Strategic Indicators & European Innovation Metrics
Who it's for
Investors screening Onego Bio Ltd, competitors and partners assessing their position, and analysts who need a sourced, structured account of the entity and its technology.
Methodology & sources
DFM reports are built from primary and official sources — TED procurement notices, CORDIS and the EU Funding & Tenders Portal, EIB operations, the NATO Innovation Fund portfolio, SIPRI data, official budget documents and company disclosures — read together with the underlying legal texts. Sources are cited in the document; the report reflects them as of its publication date (22 August 2025).
Format & delivery
32-page PDF, watermarked to you (name, e-mail, order number on every page). Delivered immediately after checkout on the confirmation page and by e-mail; the personal link is valid for 72 hours and up to 5 downloads (re-issued on request). Guest checkout — no account required. Single-user licence: see the Terms of Sale.
The full analysis, not the summary
The public briefing linked above tells you what this report found; the report itself shows the full evidence and reasoning behind it, section by section. It is the complete, dated document from the DFM research desk — sources cited, delivered as a licensed PDF you can keep and cite in your own work.
Related on DFM
More Tactical reports · Synthetic Biology · Free summary of this report · All reports
Prefer unlimited access?
Prefer unlimited access? Every report like this is included in the DFM Analysis subscription. See plans →